ReviewJournal of clinical medicine2020
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of COVID 19 SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication (SARSmRNA_MS)
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.Multiple sclerosis and related disorders · 2022Pooled it
- CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.Frontiers in immunology · 2026Article
- Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.Acta neurologica Belgica · 2024Article
- Era of COVID-19 in Multiple Sclerosis Care.Neurologic clinics · 2024Review
- COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis.Vaccines · 2024Article
- Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review.Neurology and therapy · 2023Review
- The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Article
- SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.Journal of neurology · 2022Review
- Article
- COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.Neurology and therapy · 2022Article
- Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.Biomedicines · 2022Review
- A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.Multiple sclerosis and related disorders · 2022Article
- Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.Frontiers in neurology · 2022Review
- Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.Current neuropharmacology · 2022Article
- COVID-19 outcomes in persons with multiple sclerosis treated with rituximab.Multiple sclerosis and related disorders · 2022Article
- Case report: Multiple sclerosis diagnosis after anterior lumbar interbody fusion and presumed COVID-19 infection.Surgical neurology international · 2022Article
- Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS).European journal of neurology · 2021Article
- Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.Journal of neurology, neurosurgery, and psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a challenge for all participants in the healthcare system. At the beginning of the pandemic, many physicians asked themselves what risk their patients, especially those with chronic diseases, were exposed to. We present an overview of all patients with multiple sclerosis (MS) and SARS-CoV-2 infection published in the literature so far. In total, there are publications on 873 SARS-CoV-2 positive MS patients and information on the outcome can be given for 700 patients. With regard to the different disease modifying therapies (DMTs), by far the most cases were described under anti-CD20 treatment (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.